Latecomer Janumet XR suffers FDA setback
This article was originally published in Scrip
Executive Summary
Merck & Co's extended-extended release of its metformin/sitagliptin diabetes product Janumet has been the subject of an FDA complete response letter, it was revealed during the company's second-quarter earnings call.